ACTG1 and MYLK2 were gained (amplified and/or overexpressed) at 5~14% and 5~20%, respectively, in uterine mixed endometrial carcinoma (UMEC), uterine serous carcinoma (USC), uterine endometrioid carcinoma (UEC) and uterine carcinosarcoma (UCS) (Figure 2A). Here, MYLK2 is linked to endometrial serous adenocarcinoma.